Amphastar Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2017
Filed with the SEC on Aug 9, 2017 and accepted by EDGAR at Aug 9, 2017, 17:21 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 6 months2017-01-01 to 2017-06-30 | $121.9m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2017-04-01 to 2017-06-30 | $38.4m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2017-01-01 to 2017-06-30 | $72.3m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2017-04-01 to 2017-06-30 | $26.7m | us-gaap:GrossProfit |
| Gross profit | 6 months2017-01-01 to 2017-06-30 | $49.6m | us-gaap:GrossProfit |
| Research and development | 3 months2017-04-01 to 2017-06-30 | $10.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2017-01-01 to 2017-06-30 | $22.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-04-01 to 2017-06-30 | $2.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2017-01-01 to 2017-06-30 | $3.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-04-01 to 2017-06-30 | $237.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2017-01-01 to 2017-06-30 | $428.0k | us-gaap:InterestExpense |
| Income tax | 3 months2017-04-01 to 2017-06-30 | $1.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2017-01-01 to 2017-06-30 | $1.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-04-01 to 2017-06-30 | $2.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2017-01-01 to 2017-06-30 | $2.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-04-01 to 2017-06-30 | $0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2017-01-01 to 2017-06-30 | $0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-04-01 to 2017-06-30 | $0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2017-01-01 to 2017-06-30 | $0.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-04-01 to 2017-06-30 | 47,866,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2017-01-01 to 2017-06-30 | 47,962,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 6 months2017-01-01 to 2017-06-30 | $13.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2017-01-01 to 2017-06-30 | $17.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-06-30 | $82.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-06-30 | $193.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-06-30 | $444.0m | us-gaap:Assets |
| Current liabilities | At period end2017-06-30 | $63.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-06-30 | $110.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-06-30 | $333.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001297184-17-000028. Last ingested by Listed: Nov 6, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.